Skip to main content

Table 2 Estimates of the global prevalence of cryptococcal meningitis and associated death

From: Cryptococcus neoformans, a global threat to human health

 

CrAg positive cases (in thousands)a

CM cases (in thousands)

CM deaths (in thousands)

2014

2020

2007

2014

2020

2007

2014

2020

Global

278.0 (195.5–341.0)b

179.0 (133.0–219.0)

957.9 (371.7–1544)

223.1 (150.6–282.4)

152.0 (111.0–185.0)

624.7 (125.0–1124.9)

181.1 (119.4–234.3)

112.0 (79.0–134.0)

Sub-Saharan Africa

204.3 (148.4–237.8)

97.0 (73.0–120.0)

720.0 (144.0–1300.0)

162.5 (113.6–193.9)

82.0 (61.0–101.0)

504.0 (100.8–907.2)

135.9 (93.9–163.9)

71.0 (52.0–88.0)

Asia and the Pacific

52.3 (32.9–74.1)

51.0 (42.0–60.0)

133.6 (26.7–240.5)

43.2 (25.3–64.7)

44.0 (35.0–51.0)

67.2 (13.4–121)

39.7 (20.6–59.7)

26.0 (21.0–30.0)

Latin America

7.0 (3.6–11.1)

14.0 (10.0–17.0)

54.4 (10.9–97.9)

5.3 (2.6–8.9)

12.0 (9.0–14.0)

29.9 (6.0–53.8)

2.4 (1.1–4.4)

7.0 (5.0–9.0)

Europec and North America

8.9 (7.0–11.1)

15.0 (13.0–17.0)

34.5 (7.1–64.0)

7.4 (5.7–9.3)

12.0 (10.5–1.4)

15.8 (3.1–28.4)

2.5 (1.8–3.4)

7.0 (5.7–8.4)

Caribbean

1.8 (1.3–2.2)

2.0 (1.7–2.3)

7.8 (1.6–14.1)

1.4 (1.0–1.8)

1.7 (1.4–1.9)

4.3 (0.9–7.8)

0.7 (0.5–0.9)

1.0 (0.8–1.0)

Middle East and North Africa

3.6 (2.6–5.0)

0.5 (0.1–0.6)

6.5 (11.3–7.6)

3.3 (2.4–4.5)

0.4 (0.1–0.5)

3.6 (0.7–6.4)

1.9 (1.3–2.7)

0.2 (0.1–0.3)

  1. CrAg Cryptococcal antigen; CM Cryptococcal meningitis
  2. aAntigenemia data was not available for estimation of cases in 2007
  3. bData provided as mean (95% confidence interval)
  4. cThe 2020 data contains cases from Central Asia